TARRYTOWN, N.Y., March 22 /PRNewswire-FirstCall/ -- Regeneron Pharmaceuticals, Inc. today announced the appointment of Michael Aberman, M.D., as Vice President, Strategy and Investor Relations. In the Strategy role, Dr. Aberman will report directly to Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer, and for Investor Relations he will report directly to Murray A. Goldberg, Chief Financial Officer. Peter Dworkin, Vice President, will continue to be responsible for Corporate Communications, reporting to Mr. Goldberg.
"We are thrilled that Michael has joined our management team," said Dr. Schleifer. "Michael brings a unique combination of knowledge and experience gained from more than twelve years as a physician, biotech executive, and Wall Street analyst. We look forward to benefiting from his insights as we work to develop and commercialize important new medicines."
About Regeneron
Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST(R) (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, age-related macular degeneration, and certain cancers. Additional therapeutic candidates are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic conditions, and cancer. Additional information about Regeneron and recent news releases are available on Regeneron's web site at www.regeneron.com.
CONTACT: Peter Dworkin, Investor Relations, +1-914-345-7640,
peter.dworkin@regeneron.com, or Laura Lindsay, Media Relations,
+1-914-345-7800, laura.lindsay@regeneron.com
Web site: http://www.www.regeneron.com/
